Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal intergroup pancreatic cancer task force
- 1 October 2004
- journal article
- research article
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 13 (4) , 751-760
- https://doi.org/10.1016/j.soc.2004.06.009
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Farnesyltransferase inhibitorsSeminars in Oncology, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasiaSeminars in Oncology, 2002
- Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II StudyJournal of Clinical Oncology, 2002
- Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neuEuropean Journal Of Cancer, 2001
- Closing the gastrin loop in pancreatic carcinomaCancer, 2000
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971